{"filings":[{"id":759717,"accession_number":"0001213900-26-063157","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-06-01T12:01:20+00:00","items":["7.01","9.01"],"status":"ready","headline":"Jasper Therapeutics initiates strategic review including potential sale or wind-down","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board of Directors initiates comprehensive review of strategic alternatives to maximize shareholder value.","Options include sale of assets/licensing, collaboration, merger, business combination, or orderly wind-down.","Company to continue evaluating cost-saving measures to preserve cash during the process.","No defined timeline for the review; no assurance any transaction will be consummated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":581596,"accession_number":"0001213900-26-060029","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-05-21T20:01:33+00:00","items":["5.02","9.01"],"status":"ready","headline":"Jasper Therapeutics director Christian Nolet resigns; Svetlana Lucas joins audit committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Christian Nolet resigned from Board and all committees effective May 15, 2026.","Resignation not due to any disagreement with the company's operations, policies or practices.","Board appointed Svetlana Lucas, Ph.D. to the Audit Committee.","No other changes to board composition or officer roles disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":442525,"accession_number":"0001213900-26-056596","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-05-14T20:05:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q1 net loss $1.2M; refiles Phase 2b protocol for briquilimab in CSU","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents of $14.1M as of March 31, 2026, with $5.8M R&D and $5.1M G&A expenses.","Refiled Phase 2b protocol with FDA for briquilimab in chronic spontaneous urticaria; seeks funding to start H2 2026.","Jeet Mahal appointed CEO to lead next phase of clinical growth.","Positive clinical data: 67% of BEACON patients achieved complete response at 12 weeks; 75% in open-label achieved well-controlled disease.","Median follow-up >200 days; KIT-related AEs low-grade and resolved on study."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108567,"accession_number":"0001213900-26-036448","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-03-30T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper posts Q4 net loss $9.1M; cash $28.7M; appoints new CEO; reports positive CSU/asthma data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Jeet Mahal named President and CEO to lead next phase of clinical growth.","Positive CSU data: 67% complete response in BEACON Cohort 9.1; 75% in open-label extension at 12 weeks.","Preliminary asthma data from ETESIAN study shows reduced airway hyperresponsiveness after single 180mg dose.","Internal investigation found no drug product issues; KOL panel recommends enhanced site selection and screening.","Q4 2025 net loss $9.1M; year net loss $75.8M; cash and equivalents $28.7M at Dec 31, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108566,"accession_number":"0001213900-26-002329","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports 67% complete response at week 12 in additional BEACON CSU patients; dose selected for Phase 2b","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["67% (4/6) of new BEACON briquilimab patients achieved complete response at week 12; mean UAS7 drop of 31 points.","In open-label extension, 58% of 36 CSU patients achieved complete response and 75% achieved CR or well-controlled at week 12.","Median follow-up of 205 days in 63 patients; KIT-related AEs were infrequent, low-grade, and resolved without discontinuation.","Company plans to commence Phase 2b study of briquilimab in CSU in second half of 2026.","Briquilimab is an investigational anti-KIT antibody targeting mast-cell-driven diseases like CSU and CIndU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108565,"accession_number":"0001213900-26-002185","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics appoints COO Jeet Mahal as CEO; Ron Martell steps down, Thomas Wiggans named Executive Chair","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Effective Jan 5, 2026, Jeet Mahal becomes CEO and President; he also joins the Board as Class III director.","Outgoing CEO Ron Martell's departure is without cause; he receives 18 months base salary plus COBRA for up to 18 months.","Thomas Wiggans, current Board Chair, appointed Executive Chair effective Jan 5, 2026.","Mahal's annual salary increased to $600,000 with eligibility for performance bonus up to 50% of base salary.","Company to host investor webinar on Jan 8, 2026 to present updated data from BEACON study and open-label extension in CSU/CIndU."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125005,"accession_number":"0001213900-25-116943","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-12-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports positive ETESIAN asthma data; BEACON investigation clears drug product","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Single 180mg briquilimab reduced sputum eosinophils from 10.3% to 2.32% at 6 weeks post-allergen challenge.","Late asthmatic response FEV1 AUC improved 25.4% at 6 weeks and 23.3% at 12 weeks vs baseline.","BEACON investigation: no drug product issues; 9 of 10 US patients likely did not have mast cell-driven CSU.","Briquilimab well-tolerated; no dose-limiting toxicities; safety profile consistent with prior studies.","Final BEACON data expected Q1 2026; Phase 2b CSU study planned to start mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125004,"accession_number":"0001213900-25-107874","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Q3 net loss $18.7M; BEACON investigation finds no drug quality issues; cash $50.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.7M ($1.13 per share); R&D expense $14.4M, G&A $4.8M.","Cash $50.9M at Sep 30; completed $30M stock/warrant offering extending runway into H1 2026.","BEACON investigation: no drug substance or product issues; focus now on clinical site processes.","Final BEACON conclusions expected Q4 2025; additional data from BEACON and OLE in H1 Q1 2026 for Phase 2b dose selection.","Initial data from ETESIAN asthma study planned for Q4 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.18,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141702,"accession_number":"0001213900-25-089584","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics prices $30M public offering, updates BEACON CSU investigation progress","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds ~$30M from offering of 11.67M shares + warrants at $2.43/share; closing expected Sept 22.","BEACON CSU investigation rules out drug substance/product issues; focus shifts to clinical site activity.","Investigation completion expected in Q4 2025 with KOL panel review for Phase 2b CSU study integration.","Use of proceeds: continued development of briquilimab in mast-cell diseases and general corporate expenses.","Common warrants exercisable at $2.92, 6-month lockout, 4-year term; pre-funded warrants at $0.0001 exercise."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141701,"accession_number":"0001213900-25-075678","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q2 net loss $26.7M; cuts workforce 50%, probes BEACON lot issue","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $26.7M ($1.74 per share); cash and equivalents $39.5M as of June 30, 2025.","BEACON study: 89% complete response in 240/360 mg single-dose cohorts; investigation into 240mg Q8W/240/180mg Q8W cohorts due to potential product lot variability.","Workforce reduction of ~50% to focus on urticaria; CMO Dr. Edwin Tucker stepped down, succeeded by Dr. Daniel Adelman as interim.","Halted non-mast cell programs (SCID, asthma ETESIAN study) to concentrate on briquilimab in CSU and CIndU."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141700,"accession_number":"0001213900-25-062194","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-07-09T23:59:59+00:00","items":["2.05","5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics cuts workforce ~50%, halts non-urticaria programs; CMO departs","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Workforce reduction of ~50% and halting of all non-chronic urticaria programs.","Estimated $1.8M-$2.2M in severance cash expenditures through Q3 2025.","CMO Edwin Tucker departs effective Aug 1, 2025; receives 12 months base salary and COBRA.","Dr. Daniel Adelman appointed Acting Chief Medical Officer effective Aug 1, 2025.","Focus on briquilimab in CSU/CIndU; data from BEACON/SPOTLIGHT expected later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141699,"accession_number":"0001213900-25-061632","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-07-07T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports 89% complete response in single-dose CSU cohorts, but drug lot issue delays Phase 2b to mid-2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["8 of 9 (89%) patients in 240mg and 360mg single-dose cohorts achieved complete response (UAS7=0).","8 of 11 (73%) in 180mg Q8W open-label extension achieved complete response at week 12.","Results from 240mg Q8W and 240mg→180mg Q8W cohorts confounded by drug product lot issue affecting 10 of 13 patients.","ETESIAN asthma study halted due to same lot issue; SCID development stopped; cost cutting and potential restructuring.","Additional BEACON data expected Q4 2025; Phase 2b CSU study start delayed to mid-2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141698,"accession_number":"0001213900-25-061471","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-07-03T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Jasper Therapeutics shareholders elect directors, ratify PwC, approve say-on-pay","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Elected Kurt von Emster, Scott Brun, and Vishal Kapoor as Class I directors with >8.4M votes each.","Ratified PwC as independent auditor for FY 2025: 11,992,658 for, 18,646 against.","Advisory say-on-pay approved: 8,108,299 for, 536,022 against, 9,718 abstentions.","Advisory vote on frequency favored every 1 year (8,580,886 votes); company will hold annual say-on-pay votes.","Turnout ~80% (12,014,527 of 15,022,122 shares represented)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159596,"accession_number":"0001213900-25-054465","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-06-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics: 92% complete response in 180mg cohort of briquilimab SPOTLIGHT study in CIndU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["11 of 12 participants (92%) achieved complete response; 12 of 12 (100%) achieved clinical response within 8-week analysis.","Tryptase levels below lower limit of quantification in 10 of 12 (83%); no SAEs or grade 3+ AEs reported.","Response rapid: 66% achieved CR/PR by week 2; 58% maintained clinical response through week 8.","No hair/skin color changes; mild transient neutrophil drops in 6 of 12 (50%), median resolution 16 days.","Conference call and webinar on June 16, 2025 at 8:00 AM EDT to present data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159595,"accession_number":"0001213900-25-042017","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q1 2025 net loss $21.2M; cash $48.8M; briquilimab programs on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $21.2M ($1.41 per share) for Q1 2025; R&D expenses $16.2M, G&A $5.6M.","Cash and equivalents totaled $48.8M as of March 31, 2025.","BEACON CSU study data (including OLE) expected first half of Q3 2025; Phase 2b planned for H2 2025.","SPOTLIGHT CIndU study full cohort enrolled; additional data at EAACI June 2025.","ETESIAN asthma allergen challenge study enrolling; initial data expected H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177971,"accession_number":"0001213900-25-025123","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["1.01","1.02","9.01"],"status":"ready","headline":"Jasper Therapeutics enters $100M ATM equity offering with Jefferies; terminates prior Cantor agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Company entered Open Market Sale Agreement with Jefferies LLC to sell up to $100M of common stock.","Jefferies will receive 3.0% commission on gross sales price per share; issuer has no obligation to sell.","Prior ATM agreement with Cantor Fitzgerald terminated effective March 14, 2025; no shares sold under it.","Offering will be made under new S-3 registration statement filed March 19, 2025.","No material penalties incurred from termination of Cantor agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177970,"accession_number":"0001213900-25-017656","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics reports FY2024 net loss of $71.3M; briquilimab data positive","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $71.6M at Dec 31, 2024; net loss $71.3M ($4.89 diluted EPS) for FY2024.","BEACON study in CSU: multiple dosing regimens ≥120mg showed >25-point UAS7 improvement; Phase 2b expected H2 2025.","SPOTLIGHT study in CIndU: 14 of 15 patients (93%) achieved clinical response; 83% complete response in 120mg cohort.","First patient dosed in ETESIAN asthma study; initial data expected H2 2025.","Open-label extension study commenced; initial data from ~30 patients expected mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-4.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":177969,"accession_number":"0001213900-25-001810","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2025-01-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports positive BEACON data: 240mg dose shows UAS7 drop of 26.6, 100% complete response at 8 weeks","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mean UAS7 change of -26.6 at 8 weeks in 240mg single-dose cohort (N=3); all patients achieved Complete Response (UAS7=0).","Multiple dosing regimens ≥120mg showed UAS7 reduction >25 points; clinical responses as early as 1 week post-first dose.","Serum tryptase reductions below lower limit of quantification observed; 100% of 240mg cohort at week 1.","Favorable safety profile: no dose-limiting toxicities, infrequent low-grade c-Kit blockade events, no discontinuations.","Registrational Phase 2b study in CSU expected to commence in second half of 2025; additional data by mid-2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194671,"accession_number":"0001213900-24-095175","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Jasper Therapeutics Q3 net loss $18.6M, reports positive CIndU data, discontinues LR-MDS","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.6M ($1.24 diluted EPS); cash $92.5M at Sept 30, 2024.","SPOTLIGHT study: 93% clinical response (83% complete response) in 120mg cohort; no SAEs.","Initial BEACON data in CSU expected week of Jan 6, 2025; asthma challenge study cleared in Canada/EU.","Discontinued LR-MDS program as briquilimab did not improve hematopoiesis.","R&D expenses $14.5M, G&A $5.4M for Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194670,"accession_number":"0001213900-24-087394","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-10-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Jasper reports 93% clinical response rate in SPOTLIGHT study of briquilimab in CIndU","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["14 of 15 patients (93%) achieved clinical response; 10 of 12 (83%) in 120mg cohort had complete response.","No serious adverse events or grade 3+ adverse events reported; well-tolerated with no hair/skin changes.","Initial BEACON study data in CSU expected week of January 6, 2025, including 180mg Q8W cohort.","Regulatory clearance obtained to enroll 180mg dose cohort (n=12) in SPOTLIGHT; full results H1 2025.","Significant tryptase reduction observed (66% at 2 weeks) correlating with clinical responses."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229445,"accession_number":"0001213900-24-053982","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-06-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.","Svetlana Lucas, Ph.D., appointed as Class III director effective June 18, 2024.","Lucas is Chief Business Officer at Scribe Therapeutics with 20+ years in biopharma strategy.","Received initial option grant of 15,000 shares at $23.19/share, vesting over 4 years.","Also serves on board of aTyr Pharma (Nasdaq: LIFE) and as advisor to Radar Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229444,"accession_number":"0001213900-24-051891","cik":1788028,"company_name":"Jasper Therapeutics, Inc.","ticker":"JSPR","form_type":"8-K","filed_at":"2024-06-12T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Jasper Therapeutics stockholders approve 2024 equity plans; amended employment agreements for CEO and other executives","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Stockholders voted 10.3M for, 95K against to approve 2024 Equity Incentive Plan.","Stockholders voted 10.4M for, 12K against to approve 2024 Employee Stock Purchase Plan.","CEO Martell's annual salary remains $727,272; target bonus 50% of base; severance 18 months base plus COBRA.","CFO Cross salary $476,100; COO Mahal $481,301; CMO Tucker $514,500; each target bonus 45% of base.","Company terminated prior severance plan in favor of individual employment agreements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":25264328.457593687,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}